Showing results (11-20 of 27) with videos related to
Sort By:
Pageof 3
JOP : Journal of the Pancreas|September 8, 2009
Surgical resection after TNFerade therapy for locally advanced pancreatic cancerManpreet K Chadha, Alan Litwin, Charles Levea, et al.Diseases of the Colon and Rectum|November 22, 2007
Significance of signet-ring cells in patients with colorectal cancerRashmi Pande, Annette Sunga, Charles Levea, et al.American Journal of Clinical Oncology|October 11, 2008
Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical responseMilind Javle, Amitkumar Pande, Renuka Iyer, et al.The Journal of Surgical Research|June 16, 2009
The effects of epidermal growth factor receptor activation and attenuation of the TGFbeta pathway in an orthotopic model of colon cancerMelanie Ongchin, Elizabeth Sharratt, Ivan Dominguez, et al.Oncology|July 18, 2013
Erlotinib and radiation therapy for elderly patients with esophageal cancer - clinical and correlative results from a prospective multicenter phase 2 trialRenuka Iyer, Ravi Chhatrala, Tracey Shefter, et al.Journal of Gastrointestinal Oncology|August 2, 2014
Breast cancer resistance protein (BCRP) and excision repair cross complement-1 (ERCC1) expression in esophageal cancers and response to cisplatin and irinotecan based chemotherapyAnubha Bharthuar, Sana Saif Ur Rehman, Jennifer D Black, et al.International Journal of Gastrointestinal Cancer|August 20, 2005
Expression of intestinal trefoil factor (TFF-3) in hepatocellular carcinomaThaer Khoury, Krishdeep Chadha, Milind Javle, et al.Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|April 17, 2007
CD24 expression is an independent prognostic marker in cholangiocarcinomaShefali Agrawal, Boris W Kuvshinoff, Thaer Khoury, et al.Cancer Research|June 19, 2007
Mutant PIK3CA-bearing colon cancer cells display increased metastasis in an orthotopic modelXiao-Ning Guo, Ashwani Rajput, Rebecca Rose, et al.Cancer Chemotherapy and Pharmacology|July 14, 2017
A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agentChristos Fountzilas, Ravi Chhatrala, Nikhil Khushalani, et al.Pageof 3